Indications
Chronic hepatitis C
This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh ... Read more
This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). This is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Dosage And Administration
Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc.
Recommended dosage: Three tablets (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) taken orally once daily with food.
See recommended treatment duration in tables below-
Treatment-Naïve Patients: HCV Genotype 1, 2, 3, 4, 5, or 6
No Cirrhosis: 8 weeks
Compensated Cirrhosis (Child-Pugh A): 12 weeks
Treatment-Experienced Patients: HCV Genotype 1
Patients Previously Treated With a Regimen Containing: An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor
No Cirrhosis: 16 weeks
Compensated Cirrhosis (Child-Pugh A): 16 weeks
Treatment-Experienced Patients: HCV Genotype 1
Patients Previously Treated With a Regimen Containing: An NS3/4A PI without prior treatment with an NS5A inhibitor
No Cirrhosis: 12 weeks
Compensated Cirrhosis (Child-Pugh A): 12 weeks
Treatment-Experienced Patients: HCV Genotype 1, 2, 4, 5 or 6
Patients Previously Treated With a Regimen Containing: PRS
No Cirrhosis: 8 weeks
Compensated Cirrhosis (Child-Pugh A): 12 weeks
Treatment-Experienced Patients: HCV Genotype 3
Patients Previously Treated With a Regimen Containing: PRS
No Cirrhosis: 16 weeks
Compensated Cirrhosis (Child-Pugh A): 16 weeks
Side Effects
In subjects receiving this preparation, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue.
Precautions And Warnings
Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Pregnancy And Lactation
No adequate human data are available to establish whether or not this preparation poses a risk to pregnancy outcomes. It is not known whether the components of this preparation are excreted in human breast milk, affect human milk production, or have effects on the breastfed infant. When administered to lactating rodents, the components of this preparation were present in milk, without effect on growth and development observed in the nursing pups. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for this preparation and any potential adverse effects on the breastfed child from this preparation or from the underlying maternal condition.